She joined Neuroderm
(Nasdaq: NDRM) as the vice president of Research and was promoted to the position of VP R&D in 2010.
TSE Code: 4508) has closed its acquisition of Israeli pharmaceutical company NeuroDerm
M2 EQUITYBITES-October 24, 2017-Mitsubishi Tanabe Pharma Closes Acquisition of Israeli Drugmaker NeuroDerm
Global law firm White & Case LLP advised NeuroDerm
Israeli clinical-stage pharmaceutical company NeuroDerm
Ltd (NASDAQ: NDRM) has been acquired by Mitsubishi Tanabe Pharma Corporation (TSE: 4508), the company confirmed on Wednesday.
15 September 2017 - Shareholders of Israeli pharmaceutical company NeuroDerm
is in Phase III clinical trials in the United States with results expected later this year.
Israeli clinical-stage developer of drug-device combinations for central nervous system (CNS) disorders, NeuroDerm
Ltd (NASDAQ: NDRM), has signed a definitive acquisition agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) (TSE: 4508), the company said on Monday.
, established in 2004, develops transdermal drugs for the treatment of various CNS diseases.
4 August 2017 - Israeli pharmaceutical company NeuroDerm
, a clinical stage pharmaceutical company, has commenced a phase III clinical trial assessing NDO612L, intended for the treatment of Parkinson's disease, it was reported yesterday.
is a clinical stage pharmaceutical company, specializing in transdermal therapies for CNS diseases.